Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [18F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis

Scandinavian Journal of Urology

Volumn 49, Issue 5, 2015, Pages 345-353

  Evangelista, Laura ^a   Cimitan, Marino ^b   Zattoni, Fabio ^c   Guttilla, Andrea ^c   Zattoni, Filiberto ^c   Saladini, Giorgio ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bone scan; choline PET; computed tomography; prostate cancer; staging

Indexed keywords

CHOLINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; FLUORINE; FLUOROCHOLINE;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE SCINTISCANNING; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTERMEDIATE RISK POPULATION; INTERMETHOD COMPARISON; LYMPH NODE; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ABDOMEN; ANALOGS AND DERIVATIVES; BONE NEOPLASMS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; PELVIS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATE TUMOR; RISK; SECONDARY; VERY ELDERLY;

ABDOMEN; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHOLINE; FLUORINE RADIOISOTOPES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; PELVIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84937535060     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2015.1005665     Document Type: Article

References (37)

1. GLOBOCAN 2012: estimation cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer. Available from http://globocan.iarc.fr/.
2. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: A summary of the literature. J Urol 2004;171:2122-7.
3. Hricak H, Choyke P, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: A multidisciplinary perspective. Radiology 2007;243:28-53.
4. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88-95.
5. Briganti A, Kames J, Da Pozzo LF, Corazzini C, Gallina A, Suardi N, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer: A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55:261-70.
6. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Radical prostatectomy for clinical stage T3a disease. Cancer 2007;109:1273-8.
7. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis. Clin Radiol 2008;63:387-95.
8. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 2006;24:396-402.
9. Schaffer DL, Pendergrass H. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976;121:431-4.
10. Thurairaja R, McFarlane J, Traill Z, Persad R. State-of-The-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 2004;94:268-71.
11. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
12. Scherr D, Swiddle P, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003;2003:14-24.
13. Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, et al. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis 2014;17: 57-63.
14. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baseric T, et al. [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387-98
15. Reske SN, Blumstein N, Neumaier B, Gottfiried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006;47:1249-54.
16. Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006;47:262-9.
17. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-8.
18. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-Choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008;54:392-401.
19. Häcker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F] fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006;176:2014-18.
20. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:45-53.
21. Rietbergen DD, van der Hiel B, Vogel W, Stokkel MP. Mediastinal lymph node uptake in patients with prostate carcinoma on 18F-choline PET/CT. Nucl Med Commun 2011;32:1143-7.
22. Budiharto T, Joniau S, Lerut E, Van den Bergh L, Mottaghy F, Deroose CM, et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011;60:125-30.
23. de Jong IJ, Prium J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331-5.
24. Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF, et al. [F18]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur J Cancer 2010;46:449-55.
25. Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: A systematic literature review and meta-analysis. Eur Urol 2013;63:1040-8.
26. Clark T, Parekh DJ, Cookson MS, Chang SS, Smith ER Jr, Wells N, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003;169:145-7.
27. Flanigan RL, Shankay TV. The natural history of human prostate cancer. In Raghavan D, Scher HI, Leibel SA, Lange PH, editors. Principles and practice of genitourinary oncology. Philadelphia, PA: Lippincott-Raven; 1997. p 443-550.
28. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of (18)fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999;29:623-9.
29. Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical application. Eur J Radiol 2011;80:e50-6.
30. Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, Pettinato V, et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 2010;24:485-92.
31. Picchio M, Spinapollice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [11C] Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39:13-26.
32. McCarthy M, Siew T, Campbell A, Lenzo M, Spry N, Vivian J, et al. 18F-fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 2011;38:14-22.
33. Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, Tombal B, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: A European multiinstitutional study of 712 patients. Eur Urol 2010;58:1-7.
34. Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, et al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2011;107:765-70.
35. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, et al. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy 2013;12: 204-9.
36. Beheshti M, Vali R, Waldebìnberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: A comparative study. Eur J Nucl Med Mol Imaging 2008;35: 1766-74.
37. Evangelista L, Zattoni F, Guttilla A, Cervino AR, Gregianin M, Burei M, et al. High risk and very high risk prostate cancer and the role of choline PET/CT at initial staging. EANM Congress 2013;40:P271.